Journal of Clinical Trials
Open Access

Abstract

Differential Behavior of Bone Turnover Markers in Women with Bone Metastatic Breast Cancer or Osteoporosis

Ana Laura Soares*, Jose Gilberto Henrique Vieira, Linda Denise Fernandes Moreira, Andre Goncalves da Silva, Marise Lazaretti Castro, Sergio Daniel Simon, Luiz Henrique Gebrim and Afonso Celso Pinto Nazario

Background: This study was designed to describe Bone Turnover Marker (BTM) profiles in women.

Patients and methods: In all, 197 patients (age 61 (36-90) years) comprising five groups were studied: Osteoporosis with (OPBP+) or without (OPBP-) bisphosphonate use; bone metastatic breast cancer with (BMBP+) or without (BMBP-) BP use; and healthy controls without BP (CBP-) use. Procollagen type 1 amino-terminal Propeptide (P1NP) and Carboxy-terminal Telopeptideof type 1 collagen (CTX) wereanalyzed.

Results: The medians (25%-75%; ng/mL) for P1NP were as follows: BMBP (236.95(165.0-328.0))> CBP(47.25(33.5-63.7))=OPBP-(50.9(37.4-63.9))>BMBP+(26.9(11.8-46.3))=OPB+(19.5(12.6-27.3)). The medians (25%-75%; ng/mL) for CTX wereas follows: BMBP-(0.567(0.457-0.803))=OPBP-(0.360(0.318-0.650))>CBP-(0.297(0.203-0.402))>BMBP +(0.101(0.052-0.202))=OPBP+(0.141(0.047-0.186)).

Conclusion: P1NP>145 ng/mL completely differentiated those with BMs. CTX<0.200 ng/mL differentiated those using BPs.

Published Date: 2023-04-18; Received Date: 2023-01-11